Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its Q4 2024 earnings release for February 27, 2025, after market close. The company will host a conference call at 2:00 p.m. Pacific Time to discuss financial results.
Amphastar is a bio-pharmaceutical company specializing in developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company also sells insulin API products, with most finished products distributed through group purchasing organizations and drug wholesalers for hospital or urgent care clinical settings.
The company highlights its transition towards high-value and high-growth areas market, including the integration of BAQSIMI®, and its focus on branded products, proprietary products, and biosimilars.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha programmato il rilascio dei risultati finanziari per il quarto trimestre del 2024 per il 27 febbraio 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 14:00, ora del Pacifico, per discutere i risultati finanziari.
Amphastar è un'azienda biofarmaceutica specializzata nello sviluppo, produzione e commercializzazione di prodotti iniettabili, per inalazione e intranasali generici e proprietari, tecnicamente complessi. L'azienda vende anche prodotti API per insulina, con la maggior parte dei prodotti finiti distribuiti attraverso organizzazioni di acquisto di gruppo e grossisti farmaceutici per ospedali o ambienti clinici di pronto soccorso.
L'azienda sottolinea la sua transizione verso aree di mercato ad alto valore e ad alta crescita, inclusa l'integrazione di BAQSIMI®, e il suo focus su prodotti di marca, prodotti proprietari e biosimilari.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha programado la publicación de sus resultados del cuarto trimestre de 2024 para el 27 de febrero de 2025, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a las 2:00 p.m., hora del Pacífico, para discutir los resultados financieros.
Amphastar es una empresa biofarmacéutica especializada en el desarrollo, fabricación y comercialización de productos inyectables, de inhalación e intranasales genéricos y propios, que son técnicamente desafiantes. La empresa también vende productos API de insulina, siendo la mayoría de los productos terminados distribuidos a través de organizaciones de compra grupal y mayoristas de medicamentos para entornos clínicos de hospitales o atención urgente.
La empresa destaca su transición hacia mercados de alta valor y alto crecimiento, incluida la integración de BAQSIMI®, y su enfoque en productos de marca, productos propios y biosimilares.
암파스타 제약 (NASDAQ:AMPH)는 2025년 2월 27일 시장 마감 후 2024년 4분기 실적 발표를 예정하고 있습니다. 이 회사는 태평양 표준시 기준 오후 2시에 재무 결과에 대해 논의하기 위한 컨퍼런스 콜을 진행할 예정입니다.
암파스타는 기술적으로 도전적인 일반 및 독점 주사제, 흡입제 및 비강 제품의 개발, 제조 및 마케팅을 전문으로 하는 생물 제약 회사입니다. 이 회사는 인슐린 API 제품도 판매하며, 대부분의 완제품은 병원이나 응급 치료 임상 환경을 위한 그룹 구매 조직 및 약품 도매업체를 통해 유통됩니다.
회사는 BAQSIMI® 통합을 포함하여 고부가가치 및 고성장 시장으로의 전환을 강조하며, 브랜드 제품, 독점 제품 및 바이오시밀러에 집중하고 있습니다.
Amphastar Pharmaceuticals (NASDAQ:AMPH) a prévu la publication de ses résultats du quatrième trimestre 2024 pour le 27 février 2025, après la clôture des marchés. L'entreprise tiendra une conférence téléphonique à 14h00, heure du Pacifique, pour discuter des résultats financiers.
Amphastar est une entreprise biopharmaceutique spécialisée dans le développement, la fabrication et la commercialisation de produits injectables, inhalés et intranasaux, génériques et propriétaires, techniquement complexes. L'entreprise vend également des produits API d'insuline, la plupart des produits finis étant distribués par le biais d'organisations d'achat de groupe et de grossistes en médicaments pour des environnements cliniques hospitaliers ou de soins urgents.
L'entreprise souligne sa transition vers des marchés à forte valeur et à forte croissance, y compris l'intégration de BAQSIMI®, et son accent sur les produits de marque, les produits propriétaires et les biosimilaires.
Amphastar Pharmaceuticals (NASDAQ:AMPH) hat die Veröffentlichung seiner Ergebnisse für das vierte Quartal 2024 auf den 27. Februar 2025 nach Börsenschluss angesetzt. Das Unternehmen wird um 14:00 Uhr pazifischer Zeit eine Telefonkonferenz abhalten, um die finanziellen Ergebnisse zu besprechen.
Amphastar ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung, Herstellung und Vermarktung technisch anspruchsvoller generischer und proprietärer injizierbarer, inhalierbarer und intranasaler Produkte spezialisiert hat. Das Unternehmen verkauft auch Insulin-API-Produkte, wobei die meisten Fertigprodukte über Gruppenbeschaffungsorganisationen und Arzneimittelgroßhändler für klinische Umgebungen in Krankenhäusern oder Notfallbehandlungen vertrieben werden.
Das Unternehmen hebt seinen Übergang zu hochpreisigen und wachstumsstarken Marktbereichen hervor, einschließlich der Integration von BAQSIMI®, und konzentriert sich auf Markenprodukte, proprietäre Produkte und Biosimilars.
- None.
- None.
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Fourth quarter of 2024 ended December 31, 2024, after the market closes on Thursday, February 27, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI®, including its potential for continued revenue growth, the success of our integration of BAQSIMI®, the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Amphastar Pharmaceuticals (AMPH) release Q4 2024 earnings?
How can investors access AMPH's Q4 2024 earnings conference call?
What are the main product categories of Amphastar Pharmaceuticals (AMPH)?
What is AMPH's distribution strategy for its finished products?
